University Of California, San Francisco

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Lymphoma, Non-Hodgkin

Interventions: Drug: Carfilzomib
Drug: Bendamustine
Drug: Rituximab

First Posted Date: 2014-07-10

Last Posted Date: 2021-04-23

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 10

Registration Number: NCT02187133

Locations: 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
University of California, Davis, Davis, California, United States

Connecting Resources for Urban Sexual Health

Not Applicable

Completed

Conditions: HIV
Sexually Transmitted Infections

Interventions: Other: Testing and linkage to care for Y/MSM
Behavioral: Engagement and retention for HIV-positive Y/MSM in care
Other: Engagement and retention for HIV-negative Y/MSM in sexual health services
Drug: Stribild PEP Substudy

First Posted Date: 2014-07-08

Last Posted Date: 2024-12-12

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 378

Registration Number: NCT02183909

Locations: 🇺🇸
Downtown Youth Clinic, Oakland, California, United States

DuoPACT Pilot Intervention

Not Applicable

Completed

Conditions: HIV/AIDS

Interventions: Behavioral: DuoPACT
Behavioral: Life Steps

First Posted Date: 2014-07-04

Last Posted Date: 2024-02-15

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 60

Registration Number: NCT02181881

Locations: 🇺🇸
Center for AIDS Prevention Studies, San Francisco, California, United States

Assessment of Cerebral Microvascular Circulation

Not Applicable

Withdrawn

Conditions: Cerebral Microvascular Circulation

Interventions: Procedure: Mechanical ventilation adjustment

First Posted Date: 2014-07-02

Last Posted Date: 2019-01-08

Lead Sponsor: University of California, San Francisco

Registration Number: NCT02179840

Locations: 🇺🇸
UCSF, San Francisco, California, United States

GA-68 DOTA-TOC of Somatostatin Positive Malignancies

Phase 1

Terminated

Conditions: Neuroendocrine Tumor
Carcinoid Tumors
Neuroblastoma
Paraganglioma

Interventions: Procedure: Computed Tomography (CT)
Drug: Gallium Ga 68-Edotreotide
Procedure: Magnetic Resonance Imaging (MRI)
Procedure: Positron Emission Tomography (PET)

First Posted Date: 2014-06-30

Last Posted Date: 2019-11-12

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 300

Registration Number: NCT02177773

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Sirolimus Prophylaxis for aGVHD in TME SCID

Phase 2

Withdrawn

Conditions: Stem Cell Transplant
Severe Combined Immunodeficiency
Transplacental Maternal Engraftment

Interventions: Drug: Sirolimus

First Posted Date: 2014-06-30

Last Posted Date: 2015-12-03

Lead Sponsor: University of California, San Francisco

Registration Number: NCT02177760

Locations: 🇺🇸
Benioff Children's Hospital at UCSF Medical Center, San Francisco, California, United States

Reducing Distress And Improving Glycemic Control In Adults With Type 1 Diabetes

Not Applicable

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Behavioral: 'KnowIt'
Behavioral: 'OnTrack'

First Posted Date: 2014-06-26

Last Posted Date: 2019-03-25

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 301

Registration Number: NCT02175732

Locations: 🇺🇸
UC San Francisco, Family and Community Medicine Dept., San Francisco, California, United States

Nepal Elimination of Trachoma Study

Phase 2

Withdrawn

Conditions: Trachoma

Interventions: Drug: Azithromycin

First Posted Date: 2014-06-26

Last Posted Date: 2015-05-21

Lead Sponsor: University of California, San Francisco

Registration Number: NCT02176057

Locations: 🇳🇵
Geta Eye Hospital, Geta, Kailali, Nepal

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Adenocarcinoma

Interventions: Drug: Goserelin Acetate
Behavioral: Behavioral Dietary Intervention
Other: Laboratory Biomarker Analysis
Other: Counseling
Other: Educational Intervention
Drug: Leuprolide Acetate
Other: Quality-of-Life Assessment
Behavioral: Exercise Intervention
Drug: Triptorelin Pamoate

First Posted Date: 2014-06-20

Last Posted Date: 2020-07-23

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 57

Registration Number: NCT02168062

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve

Not Applicable

Terminated

Conditions: Hepatocellular Carcinoma
Chemoembolization

Interventions: Device: LC Bead

First Posted Date: 2014-05-26

Last Posted Date: 2019-09-10

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 17

Registration Number: NCT02147301

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy